Published in Circulation on May 15, 1996
Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev (2011) 2.22
Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease. Annu Rev Pharmacol Toxicol (2007) 1.74
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol (2007) 1.38
An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A (1999) 1.37
Particulate air pollution and vascular reactivity: the bus stop study. Int Arch Occup Environ Health (2007) 1.23
Endothelin. Cell Mol Life Sci (2010) 1.10
Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol (2001) 1.08
Pharmacokinetics and pharmacodynamic effects of ABT-627, an oral ETA selective endothelin antagonist, in humans. Br J Clin Pharmacol (2000) 1.07
The nitric oxide-endothelin-1 connection. Heart Fail Rev (2003) 1.06
Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. Am J Pathol (2009) 1.05
Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol (2002) 1.04
Nitric oxide, atherosclerosis and the clinical relevance of endothelial dysfunction. Heart Fail Rev (2003) 1.03
Enhanced endothelin-1 system activity with overweight and obesity. Am J Physiol Heart Circ Physiol (2011) 1.00
Endothelin. Pharmacol Rev (2016) 0.95
Regulation of vascular contractility and blood pressure by the E2F2 transcription factor. Circulation (2009) 0.93
Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev (2001) 0.93
Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart (2000) 0.92
Prolonged pharmacodynamic effects of S-0139, an intravenously administered endothelin A (ET) antagonist, in the human forearm blood flow model. Br J Clin Pharmacol (2010) 0.91
Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart (1999) 0.90
Reduced contribution of endothelin to the regulation of systemic and pulmonary vascular tone in severe familial hypercholesterolaemia. J Physiol (2014) 0.90
Physiological antagonism of endothelin-1 in human conductance and resistance coronary artery. Br J Pharmacol (2001) 0.89
The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin antagonist TAK-044. Br J Pharmacol (1996) 0.89
Systemic hypertension induced by hepatic overexpression of human preproendothelin-1 in rats. J Clin Invest (1996) 0.87
Nitric oxide-mediated modulation of the endothelin-1 signalling pathway in the human cardiovascular system. Br J Pharmacol (2001) 0.87
Repeatability of local forearm vasoconstriction to endothelin-1 measured by venous occlusion plethysmography. Br J Clin Pharmacol (2002) 0.85
Effects of ambient coarse, fine, and ultrafine particles and their biological constituents on systemic biomarkers: a controlled human exposure study. Environ Health Perspect (2015) 0.83
Role of endothelin in the control of peripheral vascular tone in human hypertension. Heart Fail Rev (2001) 0.82
Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men. Br J Clin Pharmacol (2005) 0.82
Endothelin in heart failure: a promising therapeutic target? Heart (1997) 0.81
Direct comparison of selective endothelin A and non-selective endothelin A/B receptor blockade in chronic heart failure. Heart (2005) 0.80
Reproducibility of forearm vasodilator response to intra-arterial infusion of calcitonin gene-related peptide assessed by venous occlusion plethysmography. Br J Clin Pharmacol (2005) 0.80
Increased expression of endothelin ET(B) and angiotensin AT(1) receptors in peripheral resistance arteries of patients with suspected acute coronary syndrome. Heart Vessels (2009) 0.80
Pathophysiology of chronic nitric oxide synthase inhibition-induced fetal growth restriction in the rat. Hypertens Pregnancy (2011) 0.78
Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening. Heart Fail Rev (2014) 0.77
Endothelin and endothelial dysfunction. Proc Jpn Acad Ser B Phys Biol Sci (2006) 0.76
Localization and function of ET-1 and ET receptors in small arteries post-myocardial infarction: upregulation of smooth muscle ET(B) receptors that modulate contraction. Br J Pharmacol (2000) 0.76
Pathophysiological, cardiovascular and neuroendocrine changes in hypertensive patients during the hemodialysis session. J Hum Hypertens (2014) 0.75
Vascular function and Endothelin-1: Tipping the Balance between Vasodilation and Vasoconstriction. J Appl Physiol (1985) (2016) 0.75
Aerobic vs anaerobic exercise training effects on the cardiovascular system. World J Cardiol (2017) 0.75
Therapeutic role of bosentan in hypertension: lessons from the model of perinephritic hypertension. Heart Fail Rev (2001) 0.75
A Fear-Avoidance Beliefs Questionnaire (FABQ) and the role of fear-avoidance beliefs in chronic low back pain and disability. Pain (1993) 9.57
Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. J Hypertens (1998) 4.94
Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet (1994) 4.90
Differential dynamics of alpha 5 integrin, paxillin, and alpha-actinin during formation and disassembly of adhesions in migrating cells. J Cell Biol (2001) 3.99
The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol (2000) 3.43
Core content of a course in clinical pharmacology. Br J Clin Pharmacol (1997) 2.99
Factors related to first dose hypotensive effect of captopril: prediction and treatment. Br Med J (Clin Res Ed) (1983) 2.90
Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. J Hypertens (1993) 2.59
Ultrasonic hydrophone based on short in-fiber bragg gratings. Appl Opt (1998) 2.35
Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol (1999) 2.35
Objective clinical evaluation of physical impairment in chronic low back pain. Spine (Phila Pa 1976) (1992) 2.23
Mutations in the Caenorhabditis elegans Na,K-ATPase alpha-subunit gene, eat-6, disrupt excitable cell function. J Neurosci (1995) 2.19
The endothelin family of peptides: local hormones with diverse roles in health and disease? Clin Sci (Lond) (1993) 2.18
Venous occlusion plethysmography in cardiovascular research: methodology and clinical applications. Br J Clin Pharmacol (2001) 1.97
Screening for human immunodeficiency virus: a survey of British clinical pharmacology units. Br J Clin Pharmacol (1993) 1.85
Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM (2000) 1.84
Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking: a mechanism for arterial thrombosis and myocardial infarction. Circulation (1999) 1.79
Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol (2001) 1.77
Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm. J Physiol (1989) 1.68
Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci (Lond) (2003) 1.66
Impaired microvascular dilatation and capillary rarefaction in young adults with a predisposition to high blood pressure. J Clin Invest (1997) 1.65
Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation (1998) 1.61
L-NMMA increases blood pressure in man. Lancet (1993) 1.60
Contribution of parental blood pressures to association between low birth weight and adult high blood pressure: cross sectional study. BMJ (1998) 1.60
Developing a core curriculum in clinical pharmacology and therapeutics: a Delphi study. Br J Clin Pharmacol (1997) 1.58
Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J Cell Sci (2001) 1.52
Microvascular correlates of blood pressure, plasma glucose, and insulin resistance in health. Cardiovasc Res (2002) 1.51
Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens (1998) 1.48
32-km distributed temperature sensor based on Brillouin loss in an optical fiber. Opt Lett (1993) 1.46
Aortic pulse-wave velocity. Lancet (1999) 1.45
Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res (2000) 1.43
The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol (2007) 1.38
Transversal and longitudinal images from the retina of the living eye using low coherence reflectometry. J Biomed Opt (1998) 1.36
Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology (2006) 1.34
Impaired coronary tissue plasminogen activator release is associated with coronary atherosclerosis and cigarette smoking: direct link between endothelial dysfunction and atherothrombosis. Circulation (2001) 1.32
Endothelin is a potent long-lasting vasoconstrictor in men. Am J Physiol (1989) 1.32
Endothelin ETA and ETB receptors cause vasoconstriction of human resistance and capacitance vessels in vivo. Circulation (1995) 1.31
Blood glucose monitors: a laboratory and patient assessment. Br Med J (1980) 1.30
Aortic distensibility and arterial-ventricular coupling in early chronic kidney disease: a pattern resembling heart failure with preserved ejection fraction. Heart (2008) 1.28
Comparison of forearm vasodilatation to substance P and acetylcholine: contribution of nitric oxide. Clin Sci (Lond) (1997) 1.27
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond. Heart (2005) 1.26
Autonomic neuropathy is associated with increased cardiovascular risk factors: the EURODIAB IDDM Complications Study. Diabet Med (2002) 1.24
Direct measurement of intracellular pH changes in Xenopus eggs at fertilization and cleavage. J Cell Biol (1981) 1.23
A systematic review of the use of opioid medication for those with moderate to severe cancer pain and renal impairment: a European Palliative Care Research Collaborative opioid guidelines project. Palliat Med (2011) 1.22
Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (1999) 1.21
Pulse wave analysis and arterial stiffness. J Cardiovasc Pharmacol (1998) 1.21
Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J Clin Endocrinol Metab (1995) 1.19
Measurement of plasma angiotensin II. Clin Sci (Lond) (1985) 1.19
31P NMR reveals increased intracellular pH after fertilization in Xenopus eggs. Proc Natl Acad Sci U S A (1981) 1.18
An electrical block is required to prevent polyspermy in eggs fertilized by natural mating of Xenopus laevis. Dev Biol (1982) 1.18
Simultaneous en-face imaging of two layers in the human retina by low-coherence reflectometry. Opt Lett (1997) 1.17
Pulse transit time measured from the ECG: an unreliable marker of beat-to-beat blood pressure. J Appl Physiol (1985) (2005) 1.16
Inhibition of human platelet aggregation by nitric oxide donor drugs: relative contribution of cGMP-independent mechanisms. Biochem Biophys Res Commun (2000) 1.16
Peripheral endothelial dysfunction in normal pressure glaucoma. Invest Ophthalmol Vis Sci (1999) 1.16
Role of angiotensin II in regulation of basal and sympathetically stimulated vascular tone in early and advanced cirrhosis. Gastroenterology (2000) 1.14
The endothelin system and its potential as a therapeutic target in cardiovascular disease. Pharmacol Ther (1996) 1.12
Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation (1998) 1.11
Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease. Circulation (1996) 1.11
Classification of alpha 2-macroglobulin-cytokine interactions based on affinity of noncovalent association in solution under apparent equilibrium conditions. J Biol Chem (1994) 1.11
Scottish Medicines Consortium: an overview of rapid new drug assessment in Scotland. Scott Med J (2007) 1.08
Systemic ETA receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br J Pharmacol (2001) 1.08
Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens (2000) 1.07
Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol (2001) 1.05
Peripheral vascular tone in patients with cirrhosis: role of the renin-angiotensin and sympathetic nervous systems. Cardiovasc Res (1998) 1.04
Enhanced vasodilatation to endothelin antagonism in patients with compensated cirrhosis and the role of nitric oxide. Gut (2003) 1.04
Effects of estrogen replacement on infarct size, cardiac remodeling, and the endothelin system after myocardial infarction in ovariectomized rats. Circulation (2000) 1.03
Activation of endothelin ETA receptors masks the constrictor role of endothelin ETB receptors in rat isolated small mesenteric arteries. Br J Pharmacol (1997) 1.03
Fertilization potential and electrical properties of the Xenopus laevis egg. Dev Biol (1985) 1.02
Studies with iontophoretic administration of drugs to human dermal vessels in vivo: cholinergic vasodilatation is mediated by dilator prostanoids rather than nitric oxide. Br J Clin Pharmacol (1998) 1.02
Altered peripheral vascular responses to exogenous and endogenous endothelin-1 in patients with well-compensated cirrhosis. Hepatology (2001) 1.01
Hyperuricaemia does not impair cardiovascular function in healthy adults. Heart (2004) 1.01
Intra-arterial substance P mediated vasodilatation in the human forearm: pharmacology, reproducibility and tolerability. Br J Clin Pharmacol (1997) 1.01
An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost (1997) 1.00
Oral antioxidant supplementation does not prevent acute mountain sickness: double blind, randomized placebo-controlled trial. QJM (2009) 1.00
Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation (1991) 0.99
Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension (1998) 0.99
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Circulation (1998) 0.99
Coherence imaging by use of a Newton rings sampling function. Opt Lett (1996) 0.98
Forearm vasoconstriction to endothelin-1 is mediated by ETA and ETB receptors in vivo in humans. J Cardiovasc Pharmacol (1995) 0.98
S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol (2000) 0.97
Relationship between plasma sialic acid concentration and microvascular and macrovascular complications in type 1 diabetes: the EURODIAB Complications Study. Diabetes Care (2001) 0.96
Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia (2007) 0.96
Trunk strength testing with iso-machines. Part 2: Experimental evaluation of the Cybex II Back Testing System in normal subjects and patients with chronic low back pain. Spine (Phila Pa 1976) (1993) 0.96
Vasodilator effects of endothelin-converting enzyme inhibition and endothelin ETA receptor blockade in chronic heart failure patients treated with ACE inhibitors. Circulation (1996) 0.95
The treatment of coronary artery disease in patients with chronic kidney disease. QJM (2006) 0.95
Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. Circulation (2001) 0.95
Hormonal and renal differences between low dose and high dose angiotensin converting enzyme inhibitor treatment in patients with chronic heart failure. Heart (1996) 0.94
Ultrasound findings in renal parenchymal disease: comparison with histological appearances. Clin Radiol (1994) 0.94
The Trevor Howell Lecture. Age, arterial stiffness and the endothelium. Age Ageing (1997) 0.93
Alpha 2-macroglobulin and the alpha 2-macroglobulin receptor/LRP. A growth regulatory axis. Ann N Y Acad Sci (1994) 0.93
Enalapril in hypertension with renal artery stenosis: long-term follow-up and effects on renal function. J Hypertens Suppl (1984) 0.93
Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction. Kidney Int (1998) 0.93
Similarity between the suprasystolic wideband external pulse wave and the first derivative of the intra-arterial pulse wave. Br J Anaesth (2007) 0.92
Endogenous endothelin maintains coronary artery tone by endothelin type A receptor stimulation in patients undergoing coronary arteriography. Heart (2000) 0.92
Vascular cell responsiveness to Toll-like receptor ligands in carotid atheroma. Eur J Clin Invest (2008) 0.90
Interleukin-4 and IL-10 bind covalently to activated human alpha2-macroglobulin by a mechanism that requires Cys949. J Interferon Cytokine Res (2000) 0.90
Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery. Heart (1999) 0.90